A serious mood disorder causing persistent low mood or loss of interest lasting at least two weeks — and one of the leading causes of disability worldwide.
Medically reviewed by
Dr. Mihaela G.
Major Depressive Disorder — commonly abbreviated MDD, or referred to as clinical depression — is not a prolonged bad mood or a proportionate response to difficult circumstances. It is a medically recognized illness defined by a cluster of symptoms that persist for at least two weeks and represent a marked departure from a person’s previous functioning. The two cardinal features are depressed mood most of the day, nearly every day, and loss of interest or pleasure (anhedonia) in activities that were previously enjoyed. At least one of these two symptoms must be present for the diagnosis to apply.
DSM-5-TR requires five or more of nine specific symptoms to be present during the same two-week period. Beyond depressed mood and anhedonia, these include changes in weight or appetite, sleep disturbance, observable psychomotor slowing or agitation, fatigue, feelings of worthlessness or excessive guilt, difficulty concentrating, and — critically — recurrent thoughts of death or suicidal ideation. The breadth of this symptom list reflects a clinical reality long recognized by psychiatrists: depression is a whole-body illness, not merely an emotional one.
MDD is among the most prevalent conditions in medicine. The World Health Organization consistently ranks it among the leading causes of disability-adjusted life years globally, and in high-income countries it competes with cardiovascular disease as a primary source of long-term disability. Approximately 7% of adults meet diagnostic criteria in any given year; lifetime prevalence approaches 17%. Despite these numbers, the majority of people with MDD never receive adequate treatment — or any treatment at all.
The course is highly variable. Some people experience a single episode that resolves with time and treatment; others develop recurrent episodes throughout their life, with the risk of relapse increasing meaningfully after each successive episode. Between episodes, many people return to full functioning. A significant minority, however, carry residual symptoms — low energy, mild anhedonia, cognitive slowing — that sustain vulnerability to the next episode. Longer, more severe, or inadequately treated episodes consistently produce worse long-term trajectories.
MDD is also one of the most treatable conditions in psychiatry. The combination of appropriate pharmacotherapy, evidence-based psychotherapy, and structured lifestyle changes produces meaningful remission in the majority of patients. The obstacle is rarely the absence of effective options — it is the diagnostic delay, the stigma of seeking help, and the functional impairment the illness itself creates that prevents people from accessing or sustaining care.
Depression presents differently across individuals, but several symptom clusters recur reliably. DSM-5-TR requires at least five symptoms from a defined list of nine, present most of the day for at least two consecutive weeks, with at least one of the first two criteria being depressed mood or anhedonia.
Mood and emotional symptoms
The most recognizable feature is a persistently depressed, empty, or hollow mood — often described not as sadness but as numbness, heaviness, or a flat gray quality to lived experience. Anhedonia, the loss of capacity for pleasure or interest in previously enjoyed activities, is frequently the more prominent complaint in adults and may be more apparent to the person’s family than to the person themselves. Irritability is common, particularly in adolescents and men, and may manifest as low frustration tolerance, snapping at minor provocations, or a pervasive sense of being on edge. Some individuals report feeling nothing at all — an absence of all emotional tone — which many find more disturbing than active suffering.
Neurovegetative symptoms
These reflect the biological substrate of the disorder. Sleep disturbance is nearly universal, most commonly presenting as early morning awakening or fragmented, non-restorative sleep, though hypersomnia — sleeping excessively — occurs in a significant minority and is more common in younger patients with atypical features. Appetite and weight changes can go in either direction: the classic presentation involves decreased appetite and weight loss, while the atypical specifier includes increased eating, carbohydrate craving, and weight gain. Psychomotor changes — visible slowing of movements and speech, or observable agitation such as pacing and hand-wringing — must be apparent to others, not only reported subjectively, to count as a DSM criterion.
Cognitive symptoms
Fatigue and loss of energy are among the most functionally disabling features of MDD, frequently disproportionate to actual activity level. Difficulty concentrating, slowed processing, forgetfulness, and indecisiveness are common and frequently cause patients to fear early dementia or cognitive illness. Feelings of worthlessness — a pervasive conviction of being a burden, fundamentally defective, or deserving of suffering — are distinct from ordinary regret or situational guilt. In severe episodes, guilt can reach delusional intensity, with the patient holding fixed false beliefs about having caused harm or disaster.
Suicidal ideation
Recurrent thoughts of death, passive wishes not to exist, and active suicidal ideation with or without a plan represent the ninth and most serious criterion. MDD carries the highest lifetime suicide risk of any mood disorder, with approximately 15% of those with severe recurrent depression dying by suicide. The absence of overt communication does not indicate the absence of these thoughts — they must be directly assessed at every clinical contact.
⋅ Persistent depressed, empty, or numb mood most of the day
⋅ Loss of interest or pleasure in previously enjoyed activities (anhedonia)
⋅ Feelings of worthlessness, excessive guilt, or deep self-blame
⋅ Recurrent thoughts of death, wishes not to exist, or active suicidal ideation
⋅ Difficulty concentrating, remembering details, or making decisions
⋅ Slowed thinking and significantly reduced mental sharpness
⋅ Pervasive hopelessness, helplessness, and catastrophic thinking
⋅ Impaired executive function affecting planning and completing tasks
⋅ Persistent fatigue and significant loss of energy disproportionate to activity
⋅ Sleep disturbance — insomnia, early morning awakening, or hypersomnia
⋅ Significant appetite change with notable weight loss or gain
⋅ Psychomotor slowing or agitation observable by others
⋅ Social withdrawal and avoidance of previously enjoyed activities
⋅ Neglect of personal hygiene, household responsibilities, or work obligations
⋅ Reduced communication and disengagement from family and friends
⋅ Abandonment of hobbies, routines, and basic self-care
MDD affects approximately 7% of the adult population in any given year, with lifetime prevalence estimated at 15–20%. Women are diagnosed at roughly twice the rate of men, a disparity attributed to a combination of hormonal factors, higher rates of interpersonal trauma, and gender differences in how depressive symptoms are expressed and recognized. Men with depression more frequently present with irritability, substance use, and risk-taking behavior — patterns that standard screening tools are poorly calibrated to detect.
Onset can occur at any age, but peak incidence falls in the mid-to-late twenties, with prevalence remaining elevated through midlife. Adolescents and older adults represent two populations where MDD is systematically underdetected. In teenagers, depressive symptoms are often attributed to developmental turbulence or adolescent behavior. In elderly patients, depression overlaps with cognitive decline, chronic illness, and grief — and is frequently miscategorized as dementia or normal aging.
Socioeconomic factors have a substantial and bidirectional relationship with MDD. Poverty, unemployment, housing insecurity, and exposure to adverse life events all significantly increase risk. Conversely, depression itself produces economic consequences — reduced work productivity, job loss, relationship dissolution — creating a feedback loop that entrenches disadvantage. This means the burden of MDD is not evenly distributed; it falls disproportionately on those with the fewest resources to address it.
A positive family history increases individual risk approximately threefold. Medical comorbidities — particularly chronic pain, cardiovascular disease, diabetes, stroke, and neurological conditions — substantially elevate both risk and treatment complexity. The relationship is bidirectional: depression is both a consequence and an independent risk factor for several of these conditions.
MDD has no single cause. It emerges from the interaction of biological vulnerability, psychological patterns, and environmental stressors — and any account that reduces it to one of these factors alone is clinically incomplete.
Genetic factors contribute meaningfully to risk. Twin studies estimate heritability at 40–50%, meaning genetics accounts for roughly half the variance in who develops MDD. No single gene determines the outcome; instead, a large number of common genetic variants each exert small effects, and genetic predisposition interacts strongly with early life adversity — childhood neglect, abuse, and parental loss amplify biological vulnerability substantially.
Neurobiological mechanisms are multiple and incompletely understood. Dysregulation of monoamine neurotransmitters — serotonin, norepinephrine, and dopamine — has been the dominant framework since the 1960s and remains the basis for most pharmacological treatments. This model is now understood to be incomplete. Research also implicates dysregulation of the HPA axis and elevated cortisol, inflammatory pathways (measurably elevated cytokines in a subset of patients), and structural changes in brain regions including the prefrontal cortex, hippocampus, and amygdala. Reduced hippocampal volume in chronic depression has been replicated across dozens of structural neuroimaging studies.
Cognitive vulnerability plays an independent etiological role. The cognitive model developed by Aaron Beck identifies negative schemas — deeply held beliefs about the self as worthless, the world as hostile, and the future as hopeless — as both a predisposing factor and a maintaining mechanism. These schemas predate the illness, persist into remission, and represent a meaningful target for psychological treatment.
Stressful life events, particularly losses — of relationships, employment, health, or significant people — are strongly associated with episode onset. The kindling hypothesis proposes that after each episode, progressively smaller stressors become sufficient to trigger the next one, a pattern supported by longitudinal data that helps explain why early and complete treatment matters for long-term prognosis.
MDD is diagnosed clinically — no blood test, imaging study, or biomarker currently confirms or excludes the diagnosis. The clinician establishes whether the patient meets DSM-5-TR criteria through systematic interview, longitudinal history-taking, and collateral information where available.
The core requirement is five or more of the following nine symptoms, present for most of the day, nearly every day, for at least two weeks, representing a change from the person’s previous level of functioning. At least one of the first two must be present: depressed mood most of the day; markedly diminished interest or pleasure in nearly all activities (anhedonia). The remaining seven are: significant weight or appetite change; insomnia or hypersomnia; observable psychomotor agitation or slowing; fatigue or loss of energy; feelings of worthlessness or excessive guilt; difficulty concentrating or making decisions; recurrent thoughts of death or suicidal ideation, with or without a specific plan.
Symptoms must cause clinically significant distress or functional impairment, and must not be fully attributable to a substance, medication, or another medical condition. Before diagnosing MDD, the clinician must exclude a history of manic or hypomanic episodes — their presence would indicate Bipolar I or II disorder respectively. This distinction carries serious treatment implications: antidepressants initiated without mood stabilizers in bipolar disorder can precipitate mania or mixed states.
Differential diagnosis is broad and clinically demanding. Persistent depressive disorder (dysthymia) involves lower-severity but longer-duration symptoms; the two conditions can co-occur (double depression). Grief can produce a full depressive syndrome, and DSM-5-TR allows MDD to be diagnosed in the context of bereavement if criteria are fully met. Medical causes — hypothyroidism, anemia, vitamin B12 deficiency, sleep apnea, and neurological disease — must be excluded with appropriate investigations, as they produce depressive syndromes that resolve with treatment of the underlying condition. Because bipolar depression may be clinically indistinguishable from unipolar MDD in a cross-sectional assessment, a careful lifetime mood history is essential before initiating any antidepressant treatment.
MDD has one of the strongest evidence bases in psychiatry. Approximately 60–70% of patients achieve meaningful symptom reduction with a first or second treatment attempt, and remission rates increase substantially with structured sequential approaches.
Pharmacotherapy
Selective serotonin reuptake inhibitors (SSRIs) are first-line treatment for most adults. Sertraline, escitalopram, and fluoxetine have the most favorable combination of efficacy, tolerability, and safety data. Serotonin-norepinephrine reuptake inhibitors (SNRIs) — including venlafaxine and duloxetine — are equally first-line and preferred when anxiety or chronic pain is prominent. Bupropion is a useful option when fatigue, cognitive slowing, or sexual dysfunction is a primary concern. Mirtazapine is particularly effective when severe sleep disruption and appetite loss dominate the clinical picture. For treatment-resistant presentations, older agents — tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) — retain demonstrable efficacy but require more careful clinical management.
Psychotherapy
Cognitive-behavioral therapy (CBT) is the most extensively studied psychotherapy for depression, with efficacy comparable to antidepressants in mild-to-moderate episodes and strong evidence for relapse prevention. Interpersonal therapy (IPT) targets the relational context of depressive onset and demonstrates strong evidence for both acute and maintenance phases. Behavioral activation — re-engagement with structured, rewarding activities regardless of current mood — is effective as a standalone intervention and conceptually accessible. The combination of medication and psychotherapy consistently outperforms either modality alone in moderate-to-severe presentations.
Advanced and somatic treatments
Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe, psychotic, or treatment-resistant MDD, with response rates exceeding 80% in appropriately selected candidates. The stigma attached to ECT substantially exceeds its actual risk profile in modern practice. Esketamine (Spravato), approved for both treatment-resistant depression and MDD with acute suicidal ideation, offers rapid symptom onset within hours to days — a clinically significant advance for crisis presentations. Transcranial magnetic stimulation (TMS) is non-invasive, well-tolerated, and effective in treatment-resistant cases with a milder side effect burden than ECT.
Treat exercise as a prescription, not a suggestion. Aerobic activity — 30 minutes most days at sufficient intensity to raise the heart rate — has antidepressant effects confirmed across multiple randomized controlled trials. This is a clinical intervention, not generic wellness advice. If full sessions feel impossible, start with ten minutes of walking and build from there.
Protect your sleep schedule above everything else. Depression disrupts sleep architecture, and fragmented sleep deepens depression. A consistent wake time — maintained even on weekends, even when mood is very low — is the most evidence-supported single sleep intervention. Avoid alcohol as a sleep aid; it fragments sleep cycles and reliably worsens next-day mood.
Act before motivation arrives, not after. Depression convinces you nothing will feel good, so there’s no point trying. This is the illness, not reality. Behavioral activation — scheduling small, concrete activities regardless of how you feel — is an established therapeutic principle. Engagement precedes enjoyment; waiting to feel ready is the mechanism of the trap.
Track your patterns. Mood is not random. A simple daily log — mood rating, hours of sleep, exercise, notable events — reveals patterns invisible in the moment and gives both you and your clinician actionable data rather than vague impressions of bad weeks.
Social contact is medicine, not a reward for feeling better. Depression drives withdrawal, and withdrawal reinforces depression. You do not need to feel sociable to benefit from contact. Brief, low-demand interaction — a short walk with someone, a phone call — is enough. Prolonged isolation accelerates the illness.
Limit alcohol and cannabis. Both are central nervous system depressants. People with depression frequently use them to manage distress, and both reliably worsen the course of MDD with regular use. Even modest habitual use can blunt the response to antidepressant treatment.
Take medication for longer than feels necessary. The most common reason antidepressants appear to fail is discontinuation too soon. Current guidelines recommend continuing treatment for at least 6–12 months after remission — longer after recurrent episodes. Discuss the cessation timeline with your clinician well before reducing the dose.
Structure is protective when motivation is absent. Depression thrives in unstructured time. A predictable daily routine — consistent mealtimes, a work or activity block, movement, and a wind-down ritual — provides scaffolding for the days when drive and initiative are gone entirely.
The prognosis for any individual depressive episode is generally favorable with appropriate treatment: the majority of people achieve remission within six months, and many recover full functioning. However, MDD should be understood as a recurrent illness for most people who develop it. After a first episode, approximately 50% will experience a second; after two episodes, the probability of a third approaches 70–80%. Each successive episode modestly lowers the threshold for the next.
Duration and severity carry long-term consequences. Episodes that are longer, more severe, or go untreated are associated with greater neurobiological burden — including measurable changes in hippocampal volume — and with a more complicated subsequent course. Early, complete treatment of each episode is protective not only acutely but for the trajectory of the illness over years. Residual symptoms after apparent recovery are a particularly strong predictor of relapse and warrant active clinical attention rather than acceptance.
Comorbidities substantially affect prognosis. The presence of anxiety disorders, alcohol or substance use, chronic physical illness, or personality pathology is associated with lower remission rates, more frequent recurrence, and greater functional disability. Conversely, strong social support, good premorbid functioning, early treatment initiation, and the absence of psychotic features are favorable prognostic indicators.
Depression is often compared unfavorably to chronic medical conditions, but the comparison cuts in both directions. Like type 2 diabetes or hypertension, MDD is a manageable chronic condition for the majority of patients. Functioning between episodes is often excellent, and many people with recurrent MDD live productive, meaningful lives with appropriate maintenance treatment, structured lifestyle factors, and learned awareness of their individual early warning signs.
Seek professional evaluation if depressed mood or loss of interest have persisted for more than two weeks without improvement — especially if sleep, appetite, or the ability to function at work or at home are affected.
Suicidal thoughts require immediate attention, regardless of whether a plan exists. This includes passive thoughts (“I’d rather not wake up,” “everyone would be better without me”) as well as active ideation. Do not wait for a scheduled appointment — contact a crisis line or go to an emergency department.
Seek urgent care if the person is not eating or drinking, cannot perform basic self-care, has lost contact with reality (hearing voices, expressing delusional beliefs), or is making preparations to harm themselves. These are psychiatric emergencies.
Someone in your life might be quietly looking for this. Share it:
These conditions share overlapping symptoms and are often misdiagnosed.
Low mood, sadness, and loss of motivation are normal human responses to difficult life events. Major depressive disorder is diagnosed when a specific cluster of at least five symptoms persists for two or more weeks, causes significant distress or functional impairment, and represents a clear change from a person’s baseline — not simply the presence of sadness. The distinction lies in duration, the range of symptoms present, and whether functioning in daily life is meaningfully affected.
Depressive episodes can remit spontaneously, and some do — particularly milder ones. However, untreated episodes tend to last significantly longer, cause greater functional damage during that time, and increase the risk of future recurrence. There is also evidence that each untreated episode may worsen the long-term course of the illness. Treatment shortens the episode, improves quality of life during recovery, and substantially reduces the probability of the next episode.
Most antidepressants require two to four weeks to produce initial symptom improvement, and the full therapeutic effect often takes six to eight weeks. Sleep and energy tend to improve earlier than mood itself. If there is no meaningful response after four to six weeks at a therapeutic dose, the treatment should be reassessed rather than continued indefinitely. After remission, most guidelines recommend continuing the medication for at least six to twelve months to reduce the risk of relapse.
No — though both involve depressive episodes that can look clinically identical, they are distinct diagnoses with different treatment implications. Bipolar depression occurs in the context of a disorder that also includes manic or hypomanic episodes; MDD has no such history. The distinction matters because antidepressants used without mood stabilizers in bipolar disorder can trigger mania or mixed states. A thorough lifetime mood history is essential before initiating antidepressant treatment for any depressive presentation.
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018). Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry, 75(4), 336–346. PubMed
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. PubMed
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. PubMed
Malhi, G. S., & Mann, J. J. (2018). Depression. The Lancet, 392(10161), 2299–2312. PubMed
Cuijpers, P., Karyotaki, E., Weitz, E., Andersson, G., Hollon, S. D., & van Straten, A. (2014). The effects of psychotherapies for major depression in adults on remission, recovery and improvement: a meta-analysis. Journal of Affective Disorders, 159, 118–126. PubMed
